Deodhar, A, Helliwell, P, Boehncke, W-H et al. (8 more authors) (2020) P262 Guselkumab, an anti-interleukin-23p19 monoclonal antibody, in patients with active PsA who were biologic-naïve or prior TNFα inhibitor-treated: week 24 results of a Phase 3, randomised, double-blind, placebo-controlled study. In: British Society for Rheumatology Annual Conference, 20-22 Apr 2020, Online.
Metadata
Item Type: | Conference or Workshop Item |
---|---|
Authors/Creators: |
|
Keywords: | adrenal corticosteroids; antirheumatic drugs, disease-modifying; glucocorticoids; adultmonoclonal antibodies; anti-inflammatory agents, non-steroidal; disclosure; interleukins; prostate-specific antigen; psoriasis; randomization; safety; skin manifestations; immunoglobulin a; infections; mineralocorticoids; quality of life; enthesitis; frequency of responses; surrogate endpoints; sf-36; adverse event; physical function; dactylitis; apremilast; employee; guselkumab |
Dates: |
|
Institution: | The University of Leeds |
Academic Units: | The University of Leeds > Faculty of Medicine and Health (Leeds) > School of Medicine (Leeds) > Institute of Rheumatology & Musculoskeletal Medicine (LIRMM) (Leeds) > Inflammatory Arthritis (Leeds) |
Depositing User: | Symplectic Publications |
Date Deposited: | 06 Nov 2020 15:36 |
Last Modified: | 06 Nov 2020 15:36 |
Status: | Published |
Identification Number: | 10.1093/rheumatology/keaa111.255 |
Related URLs: | |
Open Archives Initiative ID (OAI ID): | oai:eprints.whiterose.ac.uk:164130 |
Download not available
A full text copy of this item is not currently available from White Rose Research Online